Singh, M.D, DABFM, DABOM, system medical director of weight management and obesity medicine at Henry Ford Health
And until the medical establishment adopts better metrics, understanding exactly where you fall on the BMI scale is the first step toward accessing GLP-1 therapy
Hopefully, competition may drive price pressure or encourage development of biosimilars/generics in the long term
Demand soared after the FDA approved Wegovy and Zepbound for weight loss in 2021 and 2023, respectively
Beyond its metabolic functions, GLP-1 signaling has been implicated in cardiovascular protection and neurotrophic processes, highlighting its pleiotropic physiological roles [5]
They may deliver more weight loss, work through different hormone pathways, and even offer a pill option for people who dont want injections